The vaccine consists of a “bivalent” booster dose, meaning that half protects against the original strain of the virus, and the other half against the omicron variant.
The formulation “produces a strong immune response” against both, including the BA.4 and BA.5 omicron sub-variants, the UK Medicines and Healthcare Products Regulatory Agency said, according to the AFP news agency.
first approval
The CEO of Moderna, Stephane Bancel, highlighted “the important role” that this “new generation” of vaccines in protection against Covid-19.
According to him, the United Kingdom is the first country to approve a bivalent vaccine against omicronthe most widespread variant in Europe.
The new serum was approved by the regulatory authority “for adult booster doses” and it was concluded that “the new vaccine meets its standards for safety, quality and efficacy.”
The side effects are “typically mild” and similar to those seen in the original vaccines against the disease causing the pandemic, the regulatory body said.
Last week, the European Medicines Agency (EMA) declared that it could approve a Pfizer/BioNTech anticovid vaccine this fall against two rapidly spreading subvariants of the omicron strain: BA.4 and BA.5.
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
